The newsletter for doctors
December 12, 2021
In Nephro nutshell series, several topics have been covered. The first topic includes a case report of a young 12-year-old boy, who was diagnosed with idiopathic nephrotic syndrome (steroid-resistant) at the age of 5 years. He was treated with tolvaptan with significant improvement in edema and reduced body weight.
Another section covers the Kidney Week 2021’s virtual meeting held on November 4th – 7th which represents a case of hyponatremia from acute brain injury induced SIADH being managed with Tolvaptan. It was postulated that the tolvaptan was beneficial in promoting free water excretion and achieving eunatremia, which reduces the risk of brain edema and regulates blood pressure.
In addition, researchers developed a Kidney Project’s implantable bioartificial kidney, which promises to liberate kidney disease patients off dialysis equipment with the goal of accelerating innovation in kidney disease prevention, diagnosis, and treatment. Lastly, role of tolvaptan in heart failure patients has been duly covered.
Nutshell | The newslettter for doctors